Celecoxib promotes the efficacy of STING‐targeted therapy by increasing antitumor CD8+ T‐cell functions via modulating glucose metabolism of CD11b+Ly6G+ cells
Authors:
- 22 December 2022
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 152 (8) , 1685-1697
Abstract
Recent studies have shown that activation of the cGAS‐STING pathway is a key process in antitumor immune responses and various kinds of STING agonists have been developed for cancer immunotherapy. Despite promising preclinical studies, preliminary clinical results have shown only a modest effect of STING agonists. There is therefore a need to develop more effective treatment strategies. Based on previous observations that COX‐2 is frequently overexpressed not only in a variety of cancers but also in tumor myeloid cells and that it suppresses antitumor immunity and promotes tumor survival by producing PGE2, we investigated the antitumor effects of combination therapy with a STING agonist cGAMP and the selective COX‐2 inhibitor celecoxib in mouse models. Combination treatment with cGAMP and celecoxib inhibited tumor growth compared with either monotherapy, and the combination therapy induced both local and systemic antitumor immunity. cGAMP treatment decreased PD‐1 expression on tumor‐infiltrating T‐cells and enhanced T‐cell activation in tumor‐draining lymph nodes regardless of the presence of celecoxib. Meanwhile, although celecoxib treatment did not alter the frequency of CD4+CD25+Foxp3+ regulatory T‐cells, it enhanced the expression of costimulatory molecules and glycolysis‐associated genes in tumor‐infiltrating CD11b+Ly6G+ cells. Moreover, we also found that celecoxib decreased lactate efflux and increased the frequency of IFN‐γ‐ and TNF‐α‐producing CD8+ T‐cells in the tumor microenvironment. Taken together, our findings suggest that combined treatment with celecoxib may be an effective strategy to improve the antitumor efficacy of STING agonists.Keywords
Funding Information
- Asahikawa Medical University
- Japan Society for the Promotion of Science (JP16K19071)
This publication has 46 references indexed in Scilit:
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon PathwayScience, 2013
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNAScience, 2013
- Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T LymphocytesCancer Research, 2012
- Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activationInternational Journal of Cancer, 2011
- IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated ImmunityThe Journal of Immunology, 2011
- COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC functionBMC Cancer, 2010
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunityNature, 2009
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activityBlood, 2008
- Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor CellsCancer Research, 2007
- Inhibitory effect of tumor cell–derived lactic acid on human T cellsBlood, 2007